Triple Negative Breast Cancer News and Research

RSS

Overexpression of miR-155 promotes growth of blood vessels in tumors and metastasis

Researchers at Moffitt Cancer Center have determined that the overexpression of microRNA-155 (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, promotes the growth of blood vessels in tumors, tumor inflammation, and metastasis.

4 Apr 2013

Looking good helps women cancer patients feel better, gives more confidence to cope with disease

A year ago, Colleen Williams was into the natural look. She seldom bothered to put on makeup and she let her long, wavy, brown hair flow free. Cancer treatment changed that. These days, when she feels well enough to go to work, Williams wears her "cute hat" to cover her newly-balding head and takes a little extra time in the morning to pencil in her thinning brows and apply concealer to make her skin look a little less gray.

30 Mar 2013

Biological markers for triple-negative breast cancer (TNBC): an interview with Alexandre Templier, CEO of Quinten

Triple negative breast cancer (TNBC) is a type of cancer that has none of the three markers that are currently used for targeted chemotherapy. These markers are estrogen receptor (ER), progesterone receptor (PR) and HER2.

27 Mar 2013

Scientists develop new chemo drug that fights cancer without impacting fertility

A new gentler chemotherapy drug in the form of nanoparticles has been designed by Northwestern Medicine- scientists to be less toxic to a young woman's fertility but extra tough on cancer. This is the first cancer drug tested while in development for its effect on fertility using a novel in vitro test.

25 Mar 2013

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.

19 Mar 2013

Study shows triple-negative breast cancer cells missing key enzyme

A groundbreaking new study led by the University of Kentucky Markey Cancer Center's Dr. Peter Zhou found that triple-negative breast cancer cells are missing a key enzyme that other cancer cells contain - providing insight into potential therapeutic targets to treat the aggressive cancer.

2 Mar 2013

Two discriminating biological markers found to predict a favorable response to treatment in triple-negative breast cancer

Quinten, a strategic and operational consulting company specializing in the evaluation of biomedical data in the pharmaceutical, biotechnology and cosmetic industries, today announces the identification of two discriminating biological marker candidates which are indicative of a favorable response to treatment in women suffering from triple-negative breast cancer (TNBC).

26 Feb 2013

Copper depletion may prevent breast cancer recurrence

Early trial findings suggest that copper depletion may promote tumor dormancy in patients at high risk for recurrent breast cancer.

18 Feb 2013

FOXC2 vital to epithelial-mesenchymal transition in breast cancer

Researchers have identified a pivotal protein in a cellular transformation that makes a cancer cell more resistant to treatment and more capable of growing and spreading, making it an inviting new target for drug development.

14 Feb 2013

MicroRNA can be used to define four subtypes of triple-negative breast cancer

A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.

11 Feb 2013

Combination of two antibodies prevents growth and spread of triple-negative breast tumors

Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.

10 Feb 2013

TGFβ inhibition enhances chemotherapy action against triple negative breast cancer

Due to chemotherapy resistance and a high rate of relapse, triple negative cancers are among the most difficult breast cancers to treat. In this issue of the Journal of Clinical Investigation, researchers led by Carlos Arteaga at Vanderbilt University identified a protein, TGF-β, that is highly expressed in triple negative breast cancer cells after chemotherapy.

10 Feb 2013

SLU team discovers molecular pathway that contributes to triple-negative breast cancer

In research published in the Jan. 17 issue of The Journal of Cell Biology, a team led by Susana Gonzalo, Ph.D., assistant professor of biochemistry and molecular biology at Saint Louis University, has discovered a molecular pathway that contributes to triple-negative breast cancer, an often deadly and treatment resistant form of cancer that tends to strike younger women.

23 Jan 2013

BRCA1-deficient cancer cells take advantage of DNA repair mechanism

Cancer cells are resourceful survivors with plenty of tricks for staying alive. Researchers have uncovered one of these stratagems, showing how cells lacking the tumor suppressor BRCA1 can resume one form of DNA repair, sparing themselves from stagnation or death. The study appears in the January 21st issue of The Journal of Cell Biology.

22 Jan 2013

Aggressive breast cancer’s metastasis molecular switch identified

Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.

15 Jan 2013

18FDG–PET–CT improves breast cancer staging

A prospective study has shown fluorodeoxyglucose positron emission tomography/computed tomography to be a powerful tool for the detection of nodal and distant metastatic disease in patients with breast cancer.

17 Dec 2012

Delayed childbearing may protect against triple-negative breast cancer

Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study.

12 Dec 2012

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

10 Dec 2012

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.